A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐TSLP/anti‐IL‐13 NANOBODY® compound, in healthy volunteers

Documenti analoghi

• Morphology and stability of droplets sliding on soft viscoelastic substrates
  di: Oléron, Mathieu, et al.
  Pubblicazione: (2023)
• Indirect case‐matched comparison of anti‐ IL4Rα versus anti‐ IL5Rα on airway hyperresponsiveness
  di: Rory Chan, et al.
  Pubblicazione: (2024)
• Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers
  di: Rafael Améndola
  Pubblicazione: (2007)
• Distinct Roles for Thymic Stromal Lymphopoietin ( TSLP ) and IL ‐33 in Experimental Eosinophilic Esophagitis
  di: Anish Dsilva, et al.
  Pubblicazione: (2025)
• A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
  di: Yanina Hiriart, et al.
  Pubblicazione: (2024)